Annals of Surgical Oncology

, Volume 11, Issue 1, pp 34–39 | Cite as

Primary vaginal melanoma: A critical analysis of therapy

  • Thomas J. Miner
  • Ruby Delgado
  • Jonathan Zeisler
  • Klaus Busam
  • Kaled Alektiar
  • Richard BarakatEmail author
  • Elizabeth Poynor
Original Articles



Primary vaginal melanoma is a rare and highly malignant disease. The impact of therapy on outcomes is poorly understood.


Records of all patients treated for primary vaginal melanoma at Memorial Sloan-Kettering Cancer Center from 1977 to 2001 were reviewed. Survival analysis was performed based on appropriate patient, tumor, and treatment variables. Pathologic materials were reviewed to confirm the original diagnosis and examine appropriate clinicopathologic features.


Thirty-five women were treated for vaginal melanoma; the primary treatment selected was surgical for 69% (24) and radiotherapy for 31% (11) of the patients. Surgical removal of the tumor was achieved in 92% (22) of the 24 patients selected for surgical therapy. At operation, radical excision with en bloc removal of involved pelvic organs was performed in 50% (12) of the 24 patients, a wide excision was performed in 42% (10), and a total vaginectomy was performed in 8% (2). Elective pelvic lymph node dissection was performed in 74% (26) of the 35 cases. Lymph node metastasis was found in only 8% (2) of these 26 patients. The overall median survival was 20 months. Primary surgical therapy was associated with longer overall survival (25 vs. 13 months;P=.039). Recurrence-free survival was not associated with the extent of surgery. None of the examined clinicopathologic features were associated with survival differences.


The prognosis is poor for patients with primary vaginal melanoma. Improved clinical outcomes were associated with surgical removal of gross disease whenever possible. Because of the low rate of lymph node metastasis, elective pelvic lymph node dissection is not obligatory. In cases of surgically unresectable disease, primary radiation therapy is indicated.

Key Words

Melanoma Outcomes Treatment Tumors Vaginal 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Chang AE, Karnell LH, Menck HR. The National Cancer Database report on cutaneous and non cutaneous melanoma.Cancer 1998; 83:1664–78.PubMedCrossRefGoogle Scholar
  2. 2.
    Weinstock M. Malignant melanomas of the vulva and vagina in the United States: patterns of incidence and population-based estimates of survival.Am J Obstet Gynecol 1994;171:1225–30.PubMedGoogle Scholar
  3. 3.
    Petru E, Nagele F, Czerwenka K, et al. Primary malignant melanoma of the vagina: long-term remission following radiation therapy.Gynecol Oncol 1998;70:23–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Irvin WP, Bliss SA, Rice LW, Taylor PT, Andersen WA. Malignant melanoma of the vagina and locoregional control.Gynecol Oncol 1998;71:476–80.PubMedCrossRefGoogle Scholar
  5. 5.
    Ragnarsson-Olding B, Johansson H, Ringborg U. Malignant melanoma of the vulva and vagina: trends in incidence, age distribution, and long-term survival among 245 consecutive cases in Sweden 1960–1984.Cancer 1993;71:1893–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Cobellis L, Calabrese E, Stefanon B, Raspagliesi F. Malignant melanoma of the vagina.Eur J Gynecol Oncol 2000;21:295–7.Google Scholar
  7. 7.
    Bonner JA, Perez-Tamayo C, Reid GC, Roberts JA, Morley GW. The management of vaginal melanoma.Cancer 1988;62:2066–72.PubMedCrossRefGoogle Scholar
  8. 8.
    Reid GC, Schmidt RW, Roberts JA, Hopkins MP, Barrett RJ, Morely GW. Primary melanoma of the vagina: a clinicopathologic analysis.Obstet Gynecol 1989;74:190–9.PubMedGoogle Scholar
  9. 9.
    Van Nostrand KM, Lucci JA, Schell M, Berman ML, Manetta A, DiSaia PR. Primary vaginal melanoma: improved survival.Gynecol Oncol 1995;55:234–7.CrossRefGoogle Scholar
  10. 10.
    Konstadoulakis MM, Ricaniadis N, Driscoll DL, Karakousis CP. Malignant melanoma of the female genital system.Eur J Gynecol Oncol 1994;20:141–5.Google Scholar
  11. 11.
    Conley J, Pack JT. Melanoma of the mucous membranes of the head and neck.Otolaryngology 1974;99:315–9.Google Scholar
  12. 12.
    Wanebo HJ, Woodruff JM, Farr GH, Quan SH. Anorectal melanoma.Cancer 1981;47:1891–5.PubMedCrossRefGoogle Scholar
  13. 13.
    Brady MS, Kavolius JP, Quan SH. Anorectal melanoma: a 64 year experience at Memorial Sloan-Lettering Cancer Center.Dis Colon Rectum 1995;38:146–51.PubMedCrossRefGoogle Scholar
  14. 14.
    Ariel IM. Five year cure of a primary malignant melanoma of the vagina by local radioactive isotope therapy.Am J Obstet Gynecol 1961;82:405–7.PubMedGoogle Scholar
  15. 15.
    Chung A, Casey M, Flannery J, Woodruff J, Lewis J. Malignant melanoma of the vagina: report of 19 cases.Obstet Gynecol 1980;55:720–7.PubMedGoogle Scholar
  16. 16.
    Reaves ME, Coit DG. Melanoma: a multidisciplinary approach for the general surgeon.Surg Clin N Am 2000;80:2–21.Google Scholar
  17. 17.
    McMasters KM, Reitngen DS, Ross MI, et al. Sentinel lymph node biopsy for melanoma: controversy despite widespread agreement.J Clin Oncol 2001;19:2851–5.PubMedGoogle Scholar
  18. 18.
    Abramova L, Parekh J, Irvin WP, et al. Sentinel node biopsy in vulvar and vaginal melanoma: presentation of six cases and a literature review.Ann Surg Oncol 2002;9:840–6.PubMedGoogle Scholar

Copyright information

© The Society of Surgical Oncology, Inc 2003

Authors and Affiliations

  • Thomas J. Miner
    • 1
  • Ruby Delgado
    • 2
  • Jonathan Zeisler
  • Klaus Busam
    • 2
  • Kaled Alektiar
    • 3
  • Richard Barakat
    • 1
    Email author
  • Elizabeth Poynor
    • 1
  1. 1.Department of SurgeryMemorial Sloan-Kettering Cancer CenterNew York
  2. 2.Department of PathologyMemorial Sloan-Kettering Cancer CenterNew York
  3. 3.Department of Radiation OncologyMemorial Sloan-Kettering Cancer CenterNew York

Personalised recommendations